Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $345,330.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEXGet Free Report) Director Raymond E. Cabillot sold 7,674 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $45.00, for a total value of $345,330.00. Following the sale, the director now owns 310,978 shares of the company’s stock, valued at $13,994,010. This trade represents a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Pro-Dex Trading Down 1.8 %

Shares of NASDAQ PDEX opened at $45.70 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The stock has a market capitalization of $149.03 million, a P/E ratio of 22.74 and a beta of 0.68. Pro-Dex, Inc. has a 1-year low of $16.83 and a 1-year high of $59.60. The business has a fifty day moving average price of $39.92 and a 200 day moving average price of $37.87.

Pro-Dex (NASDAQ:PDEXGet Free Report) last announced its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Equities research analysts expect that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com cut Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday.

View Our Latest Stock Analysis on PDEX

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. OMERS ADMINISTRATION Corp acquired a new position in Pro-Dex during the 4th quarter valued at about $313,000. Millennium Management LLC acquired a new position in Pro-Dex during the 4th quarter valued at about $260,000. 683 Capital Management LLC acquired a new position in shares of Pro-Dex in the fourth quarter valued at about $739,000. Northern Trust Corp increased its holdings in shares of Pro-Dex by 14.1% in the fourth quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier’s stock valued at $1,672,000 after purchasing an additional 4,426 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Pro-Dex in the fourth quarter valued at about $433,000. 15.28% of the stock is owned by institutional investors and hedge funds.

About Pro-Dex

(Get Free Report)

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

Featured Articles

Insider Buying and Selling by Quarter for Pro-Dex (NASDAQ:PDEX)

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.